头颈癌再程放疗:组织间高剂量率近距离治疗
回顾性分析2010-2015年20例头颈癌患者接受高剂量率近距离再程放疗的临床与毒性结局。根治性治疗2年局部控制率和总生存率分别为73%和56%,姑息治疗6个月局部控制率65%;
要点
- 根治性HDR近距离再程放疗可获得较好的局部控制与总生存。
- 年龄>70岁与较差总生存相关(P = .042)。
核心结论
- 根治性HDR近距离再程放疗可提供良好的局部控制和鼓舞人心的总生存。
- 鉴于晚期毒性发生率,患者选择至关重要,尤其适用于年轻患者或接受挽救性切除者。
研究设计与样本
- 回顾性研究,纳入2010-2015年20例接受HDR近距离再程放疗的头颈癌患者,治疗意图为根治性或姑息性。
主要发现
- 根治性治疗时,2年局部控制率和总生存率分别为73%和56%。
- 姑息性治疗时,6个月局部控制率为65%。
- 年龄>70岁与较差总生存相关(P = .042)。
- 既往挽救性切除显示局部控制和总生存改善趋势(分别为P = .069和P = .063)。
临床怎么用
- 对于符合条件的头颈癌再程放疗患者,可考虑HDR近距离治疗以实现根治性或姑息性目的。
- 应严格评估患者年龄及既往挽救性切除史,权衡局部控制获益与晚期毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As high-dose-rate (HDR) brachytherapy can preferentially spare normal anatomic structures surrounding the radiation target, we report on our experience using this technique in head and neck cancer reirradiation. METHODS: Twenty patients received HDR brachytherapy reirradiation with curative or palliative intent from 2010-2015. Clinical and toxicity outcomes were recorded. Actuarial outcomes were calculated using Kaplan-Meier analysis. RESULTS: For curative treatment, actuarial 2-year rates of local control and overall survival (OS) were 73% and 56%, respectively. Palliatively, a 6-month local control rate of 65% was seen. Age >70 years was associated with poorer OS (P = .042). Prior salvage resection showed a trend toward improved local control and OS (P = .069 and P = .063, respectively). Thirty-three percent had grade 3 to 4 late toxicities. CONCLUSION: Curative-intent HDR brachytherapy reirradiation can provide excellent local control and encouraging OS. Given the late toxicity rates, patient selection is essential, with particular utility for younger patients or those treated with salvage resection.
引用
- Hegde JV, Demanes DJ, Veruttipong D, et al. Head and neck cancer reirradiation with interstitial high-dose-rate brachytherapy. Head Neck. 2018. PMID: 29573121. doi:10.1002/hed.25137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。